Adial Pharmaceuticals (ADIL) Financials

$6.65

$-0.47 (-6.60%)

As on 08-Sep-2026 16:00EDT

Market cap

$21 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	46.19	0.00	0.00	0.00	0.06	0.06
Gross Profit	-46.19	0.00	0.00	0.00	-0.06	-0.06
Operating Expenses	57.68	7.80	8.28	6.89	10.86	19.29
Operating Profit (EBIT)	-57.68	-7.80	-8.28	-6.89	-10.86	-19.29
Other Income	--	--	--	--	--	--
Profit before Tax	-57.80	-7.98	-13.20	-7.00	-10.80	-19.52
Provision for Tax	--	--	--	-1.88	0.00	-0.09
Profit after Tax (Net Income)	-57.80	-7.98	-13.20	-7.00	-12.73	-19.42
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-19.42

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	0.16	5.28	4.07	4.08	3.28	3.51
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	23.81	0.13	--	0.00	0.67	1.40
Current Liabilities	5.12	1.40	0.98	0.65	1.79	2.72
Total Liabilities	34.21	6.80	5.04	4.74	5.73	7.63

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.24	0.62	0.99	1.54	0.95	1.17
Current Assets	28.85	6.18	4.06	3.20	4.78	6.46
Total Assets	34.21	6.80	5.04	4.74	5.73	7.63
Total Debt*	--	--	--	--	0.21	0.26
Net Current Assets	23.72	4.78	3.08	2.55	2.99	3.74

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-6.49	-6.92	-6.81	-11.19	-11.95
Cash Flow from Investing Activities	--	0.15	--	1.50	--	-0.03
Cash from Financing Activities	--	8.47	7.85	4.13	9.13	13.64
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-16.54	-7.18	-17.75	-148.66	-298.16	-585.04
Cash EPS ($)	--	-7.18	-17.75	-147.38	-296.74	-583.38
Adjusted Book Value ($)	--	4.75	5.47	86.70	76.73	105.66
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-5.84	-9.31	-144.52	-261.97	-359.92
Free Cash Flow per Share ($)	--	-5.84	-9.31	-144.52	-261.97	-361.87

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-170.73	-323.80	-185.05	-351.28	-501.19
ROE (%)	-2,127.99	-170.73	-323.80	-190.27	-375.32	-518.38
ROA (%)	-273.79	-134.72	-269.86	-133.75	-190.49	-295.97
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-584.47	39.56	-88.48	35.14	39.14	-62.34
Net Profit Growth (%)	-584.04	39.56	-88.48	45.00	34.45	-78.84
EPS Growth (%)	16.37	0.60	0.88	0.50	0.49	-0.24
Book Value Growth (%)	-99.74	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.03	-0.06	-0.01	0.00	0.00
Price / Book Value	3.53	0.05	0.18	0.02	0.00	0.03
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.49	0.71	0.23	0.39	0.35	0.32
Close Price ($)	2.56	5.50	25.25	46.50	134.38	1,687.50
High Price ($)	18.90	32.50	104.25	375.00	1,781.25	3,175.00
Low Price ($)	1.31	5.41	19.13	36.25	125.06	1,050.00
Market Cap ($ Cr)	20.89	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	--	0.06	0.07
Short term debt to equity ratio	--	--	--	--	0.02	0.01
Current Ratio	5.63	4.42	4.16	4.90	2.67	2.37
Quick Ratio	5.63	--	--	--	--	--
Interest Coverage	--	--	--	--	-18.45	-4.92

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	292,632.16	114,247.29	122,959.40	1,698.24	3,098.42
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.